VJOncology is committed to improving our service to you

ESMO 2018 | Mono or combination immunotherapy for HNSCC?

VJOncology is committed to improving our service to you

Ezra Cohen

Immunotherapy has come a long way in head and neck squamous cell carcinoma. Here, Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses the use of these agents as monotherapies vs. their use in combinan moving forwards. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter